Additionally, similar techniques helped demonstrate that the anti-malaria drug Pyrimethamine (Pyr) selectively inhibits human DHFR in cancer cell lines, which is linked to its downstream inhibition of STAT3 signaling and underlies its promising anti-cancer activity [4,5,6]. Here, DHFR is linked to malaria.